206 related articles for article (PubMed ID: 19399925)
1. Effects and mechanisms of silibinin on human hepatocellular carcinoma xenografts in nude mice.
Cui W; Gu F; Hu KQ
World J Gastroenterol; 2009 Apr; 15(16):1943-50. PubMed ID: 19399925
[TBL] [Abstract][Full Text] [Related]
2. Effects and mechanisms of silibinin on human hepatoma cell lines.
Lah JJ; Cui W; Hu KQ
World J Gastroenterol; 2007 Oct; 13(40):5299-305. PubMed ID: 17879397
[TBL] [Abstract][Full Text] [Related]
3. In-vivo effects and mechanisms of celecoxib-reduced growth of cyclooxygenase-2 (COX-2)-expressing versus COX-2-deleted human HCC xenografts in nude mice.
Cui W; Hu SX; Tang ZY; Hu KQ
Anticancer Drugs; 2008 Oct; 19(9):891-7. PubMed ID: 18766003
[TBL] [Abstract][Full Text] [Related]
4. Silibinin suppresses in vivo growth of human prostate carcinoma PC-3 tumor xenograft.
Singh RP; Deep G; Blouin MJ; Pollak MN; Agarwal R
Carcinogenesis; 2007 Dec; 28(12):2567-74. PubMed ID: 17916909
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT.
Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y
Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854
[TBL] [Abstract][Full Text] [Related]
6. Silibinin strongly inhibits growth and survival of human endothelial cells via cell cycle arrest and downregulation of survivin, Akt and NF-kappaB: implications for angioprevention and antiangiogenic therapy.
Singh RP; Dhanalakshmi S; Agarwal C; Agarwal R
Oncogene; 2005 Feb; 24(7):1188-202. PubMed ID: 15558015
[TBL] [Abstract][Full Text] [Related]
7. Silybum marianum total extract, silymarin and silibinin abate hepatocarcinogenesis and hepatocellular carcinoma growth via modulation of the HGF/c-Met, Wnt/β-catenin, and PI3K/Akt/mTOR signaling pathways.
Yassin NYS; AbouZid SF; El-Kalaawy AM; Ali TM; Almehmadi MM; Ahmed OM
Biomed Pharmacother; 2022 Jan; 145():112409. PubMed ID: 34781148
[TBL] [Abstract][Full Text] [Related]
8. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria.
Zeng J; Sun Y; Wu K; Li L; Zhang G; Yang Z; Wang Z; Zhang D; Xue Y; Chen Y; Zhu G; Wang X; He D
Mol Cancer Ther; 2011 Jan; 10(1):104-16. PubMed ID: 21220495
[TBL] [Abstract][Full Text] [Related]
9. Silibinin inhibits UVB- and epidermal growth factor-induced mitogenic and cell survival signaling involving activator protein-1 and nuclear factor-kappaB in mouse epidermal JB6 cells.
Singh RP; Dhanalakshmi S; Mohan S; Agarwal C; Agarwal R
Mol Cancer Ther; 2006 May; 5(5):1145-53. PubMed ID: 16731746
[TBL] [Abstract][Full Text] [Related]
10. Silibinin efficacy against human hepatocellular carcinoma.
Varghese L; Agarwal C; Tyagi A; Singh RP; Agarwal R
Clin Cancer Res; 2005 Dec; 11(23):8441-8. PubMed ID: 16322307
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma.
Lu YS; Kashida Y; Kulp SK; Wang YC; Wang D; Hung JH; Tang M; Lin ZZ; Chen TJ; Cheng AL; Chen CS
Hepatology; 2007 Oct; 46(4):1119-30. PubMed ID: 17654699
[TBL] [Abstract][Full Text] [Related]
12. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis.
Singh RP; Gu M; Agarwal R
Cancer Res; 2008 Mar; 68(6):2043-50. PubMed ID: 18339887
[TBL] [Abstract][Full Text] [Related]
13. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo effects and mechanisms of celecoxib-induced growth inhibition of human hepatocellular carcinoma cells.
Cui W; Yu CH; Hu KQ
Clin Cancer Res; 2005 Nov; 11(22):8213-21. PubMed ID: 16299255
[TBL] [Abstract][Full Text] [Related]
15. Growth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant III.
Jiang H; Wang H; Tan Z; Hu S; Wang H; Shi B; Yang L; Li P; Gu J; Wang H; Li Z
J Biol Chem; 2011 Feb; 286(7):5913-20. PubMed ID: 21163950
[TBL] [Abstract][Full Text] [Related]
16. Silybin-mediated inhibition of Notch signaling exerts antitumor activity in human hepatocellular carcinoma cells.
Zhang S; Yang Y; Liang Z; Duan W; Yang J; Yan J; Wang N; Feng W; Ding M; Nie Y; Jin Z
PLoS One; 2013; 8(12):e83699. PubMed ID: 24386256
[TBL] [Abstract][Full Text] [Related]
17. Silibinin suppresses growth of human prostate carcinoma PC-3 orthotopic xenograft via activation of extracellular signal-regulated kinase 1/2 and inhibition of signal transducers and activators of transcription signaling.
Singh RP; Raina K; Deep G; Chan D; Agarwal R
Clin Cancer Res; 2009 Jan; 15(2):613-21. PubMed ID: 19147767
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity of dietary xanthone α-mangostin against hepatocellular carcinoma by inhibition of STAT3 signaling via stabilization of SHP1.
Zhang H; Tan YP; Zhao L; Wang L; Fu NJ; Zheng SP; Shen XF
Cell Death Dis; 2020 Jan; 11(1):63. PubMed ID: 31980595
[TBL] [Abstract][Full Text] [Related]
19. Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Gu HR; Park SC; Choi SJ; Lee JC; Kim YC; Han CJ; Kim J; Yang KY; Kim YJ; Noh GY; No SH; Jeong JH
Clin Mol Hepatol; 2015 Mar; 21(1):49-59. PubMed ID: 25834802
[TBL] [Abstract][Full Text] [Related]
20. Silibinin inhibits tumor growth through downregulation of extracellular signal-regulated kinase and Akt in vitro and in vivo in human ovarian cancer cells.
Cho HJ; Suh DS; Moon SH; Song YJ; Yoon MS; Park DY; Choi KU; Kim YK; Kim KH
J Agric Food Chem; 2013 May; 61(17):4089-96. PubMed ID: 23570653
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
